RESUMEN

Since the identification of the first HSP90 inhibitor almost two decades ago, there has been substantial progress made in the development of potent and selective molecules that inhibit this chaperone and that have anticancer activity. In turn, these compounds have been invaluable for probing how HSP90 supports the profound changes in cellular physiology that characterize the malignant state. Unfortunately, when used as single agents HSP90 inhibitors have demonstrated disappointing activity against advanced cancers in most of the clinical trials reported to date. This problem may be due to the major pharmacological liabilities of the first-generation HSP90 inhibitors that have been most extensively studied. We suggest, however, that it may well be intrinsic to the target itself. Systemically tolerable exposure to HSP90 inhibitors may not be highly cytotoxic for the majority of common clinical cancers. Instead, HSP90 inhibitors might better be used to enhance the activity of other antineoplastic agents while simultaneously reducing the capacity of tumors to adapt and evolve drug resistance; the overall result being more durable disease control. This review will focus on these fundamental issues with the goal of suggesting ways to make the clinical development of HSP90 inhibitors become less empiric and ultimately more successful.

Asunto(s)

Antineoplásicos/uso terapéutico , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Neoplasias/tratamiento farmacológico , Animales , Antineoplásicos/farmacología , Diseño de Fármacos , Humanos , Modelos Biológicos , Chaperonas Moleculares/antagonistas & inhibidores , Chaperonas Moleculares/metabolismo , Neoplasias/metabolismo

RESUMEN

N-Hydroxyformamide-class metalloprotease inhibitors were designed and synthesized, which have potent broad-spectrum activity versus matrix metalloproteases and TNF-alpha converting enzyme (TACE). Compound 13c possesses good oral and intravenous pharmacokinetics in the rat and dog.

Asunto(s)

Inhibidores Enzimáticos/farmacología , Formamidas/farmacología , Inhibidores de la Metaloproteinasa de la Matriz , Metaloendopeptidasas/antagonistas & inhibidores , Oligopéptidos/farmacología , Proteínas ADAM , Proteína ADAM17 , Animales , Perros , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacocinética , Formamidas/química , Oligopéptidos/química , Ratas , Relación Estructura-Actividad

RESUMEN

Steroid hormone receptors have become an important target in the management of breast cancers. Despite a good initial response rate, however, most tumors become refractory to current hormonal therapies within a year of starting treatment. To address this problem, we evaluated the effects of agents that bind the molecular chaperone heat shock protein 90 (Hsp90) on estrogen receptor function in breast cancer. Unstimulated estrogen and progesterone receptors exist as multimolecular complexes consisting of the hormone-binding protein itself and several essential molecular chaperones including Hsp90. We found that interaction of the Hsp90-binding drugs geldanamycin and radicicol with the chaperone destabilizes these hormone receptors in a ligand-independent manner, leading to profound and prolonged depletion of their levels in breast cancer cells cultured in vitro. Consistent with these findings, in vivo administration of the geldanamycin derivative 17-allylaminogeldanamycin (17AAG; NSC330507) to estrogen-supplemented, tumor-bearing SCID mice resulted in marked depletion of progesterone receptor levels in both uterus and tumor. Drug administration also delayed the growth of established, hormone-responsive MCF-7 and T47D human tumor xenografts for up to 3 weeks after the initiation of therapy. We conclude that in light of their novel mechanism of anti-hormone action, consideration should be given to examining the activity of 17AAG and other Hsp90-binding agents in patients with refractory breast cancer in future clinical trials, either alone or in combination with conventional hormone antagonists.

Asunto(s)

Antibióticos Antineoplásicos/farmacología , Proteínas HSP90 de Choque Térmico/metabolismo , Quinonas/farmacología , Receptores de Esteroides/efectos de los fármacos , Animales , Antibióticos Antineoplásicos/metabolismo , Benzoquinonas , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , División Celular/efectos de los fármacos , Estrógenos/uso terapéutico , Femenino , Humanos , Lactamas Macrocíclicas , Ligandos , Ratones , Ratones SCID , Trasplante de Neoplasias , Unión Proteica , Quinonas/química , Quinonas/metabolismo , Receptores de Estrógenos/efectos de los fármacos , Receptores de Estrógenos/metabolismo , Receptores de Progesterona/efectos de los fármacos , Receptores de Progesterona/metabolismo , Receptores de Esteroides/metabolismo , Factores de Tiempo , Células Tumorales Cultivadas , Útero/efectos de los fármacos , Útero/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto

RESUMEN

In attempting to develop effective anticancer immunotherapies, the relative ability of apoptotic cells to induce an immune response remains an important but controversial consideration. A novel gene-transfer approach was used by which rapid induction of pure apoptosis can be selectively achieved in a transfected tumor cell population following exposure to a semisynthetic dimerizing ligand, AP20187. Inoculation of BALB/c mice with apoptotic and viable 12B1-D1 leukemia cells, at a 12:1 ratio subcutaneously, led to early tumor growth. Heat stress up-regulated the expression of membrane heat shock proteins (HSP72 and HSP60) on apoptotic 12B1-D1 cells, and stressed apoptotic cells were capable of generating a T-cell-mediated specific antitumor response. Pulsing of stressed apoptotic leukemia cells onto syngeneic dendritic cells resulted largely in rejection of coinjected viable 12B1-D1 cells. Mice rejecting the primary 12B1-D1 inoculum were immune to the same but not to a different leukemia challenge. Our findings indicate that tumor immunogenicity is dependent on whether cells are stressed before apoptosis induction and suggest that the immune system is capable of distinguishing between stressed and nonstressed cells undergoing programmed cell death. (Blood. 2001;97:3505-3512)

Asunto(s)

Apoptosis , Proteínas de Choque Térmico/genética , Calor , Leucemia/inmunología , Leucemia/patología , Animales , Apoptosis/efectos de los fármacos , Membrana Celular/metabolismo , Chaperonina 60/genética , Células Dendríticas/inmunología , Regulación Neoplásica de la Expresión Génica , Proteínas del Choque Térmico HSP72 , Leucemia/metabolismo , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Proteínas Recombinantes de Fusión , Proteínas de Unión a Tacrolimus/genética , Transfección , Células Tumorales Cultivadas , Receptor fas/genética

RESUMEN

Chronic myelogenous leukemia (CML) is a clonal disorder characterized by proliferation of cells that possess the bcr-abl fusion gene resulting in the production of one of two possible chimeric 210-kDa tyrosine kinase proteins. Since these chimeric proteins are expressed only in leukemic cells they have the potential to serve as tumor-specific antigens for cytotoxic T lymphocytes (CTL). Using the 12B1 murine leukemia cell line, derived by retroviral transformation of BALB/c bone marrow cells with the bcr-abl (b3a2) fusion gene, we have demonstrated that intravenous inoculation of 12B1 cells into BALB/c mice results in a disseminated acute leukemia analogous to human CML in blast crisis. Histological sections of liver and spleen and polymerase chain reaction analysis of peripheral blood, bone marrow, liver, spleen and lymph nodes confirmed the presence of bcr-abl+ leukemia cells in these murine tissues, while Western blot data demonstrated the expression of the fusion protein in 12B1 cells. Immunization of mice with dendritic cells (DC) loaded with the synthetic bcr-abl chimeric nonapeptide, GFKQSSKAL, led to a 150 times higher frequency of bcr-abl-specific CTL precursors in the spleen than in mice immunized with peptide alone. In vitro re-stimulation of DC-peptide-primed splenocytes resulted in substantial secretion of interferon gamma and augmented cytolytic activity against 12B1 targets. Finally, vaccination with peptide-loaded DC significantly prolonged survival of BALB/c mice that were challenged with 12B1 leukemia. The capacity to generate bcr-abl-specific CTL in vivo by DC-based immunization may have clinical implications in the treatment of CML.

Asunto(s)

Células Dendríticas/inmunología , Proteínas de Fusión bcr-abl/inmunología , Leucemia Mielógena Crónica BCR-ABL Positiva/terapia , Oligopéptidos/inmunología , Animales , Femenino , Proteínas de Fusión bcr-abl/análisis , Inmunización , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/inmunología , Ratones , Ratones Endogámicos BALB C , Oligopéptidos/análisis , Proteínas Recombinantes de Fusión/inmunología , Linfocitos T Citotóxicos/inmunología , Células Tumorales Cultivadas

RESUMEN

IPEX is a fatal disorder characterized by immune dysregulation, polyendocrinopathy, enteropathy and X-linked inheritance (MIM 304930). We present genetic evidence that different mutations of the human gene FOXP3, the ortholog of the gene mutated in scurfy mice (Foxp3), causes IPEX syndrome. Recent linkage analysis studies mapped the gene mutated in IPEX to an interval of 17-20-cM at Xp11. 23-Xq13.3.

Asunto(s)

Proteínas de Unión al ADN/genética , Ligamiento Genético/genética , Mutación/genética , Poliendocrinopatías Autoinmunes/genética , Enteropatías Perdedoras de Proteínas/genética , Cromosoma X/genética , Secuencia de Aminoácidos , Animales , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/metabolismo , Femenino , Factores de Transcripción Forkhead , Humanos , Masculino , Ratones , Datos de Secuencia Molecular , Linaje , Fenotipo , Alineación de Secuencia , Síndrome

RESUMEN

In addition to its classic role in the cellular stress response, heat shock protein 90 (Hsp90) plays a critical but less well appreciated role in regulating signal transduction pathways that control cell growth and survival under basal, nonstress conditions. Over the past 5 years, the antitumor antibiotics geldanamycin and radicicol have become recognized as selective Hsp90-binding agents (HBA) with a novel ability to alter the activity of many of the receptors, kinases, and transcription factors involved in these cancer-associated pathways. As a consequence of their interaction with Hsp90, however, these agents also induce a marked cellular heat shock response. To study the mechanism of this response and assess its relevance to the anticancer action of the HBA, we verified that the compounds could activate a reporter construct containing consensus binding sites for heat shock factor 1 (HSF1), the major transcriptional regulator of the vertebrate heat shock response. We then used transformed fibroblasts derived from HSF1 knock-out mice to show that unlike conventional chemotherapeutics, HBA increased the synthesis and cellular levels of heat shock proteins in an HSF1-dependent manner. Compared with transformed fibroblasts derived from wild-type mice, HSF1 knock-out cells were significantly more sensitive to the cytotoxic effects of HBA but not to doxorubicin or cisplatin. Consistent with these in vitro data, we found that systemic administration of an HBA led to marked increases in the level of Hsp72 in both normal mouse tissues and human tumor xenografts. We conclude that HBA are useful probes for studying molecular mechanisms regulating the heat shock response both in cells and in whole animals. Moreover, induction of the heat shock response by HBA will be an important consideration in the clinical application of these drugs, both in terms of modulating their cytotoxic activity as well as monitoring their biological activity in individual patients.

Asunto(s)

Antibióticos Antineoplásicos/farmacología , Proteínas de Unión al ADN/fisiología , Proteínas HSP90 de Choque Térmico/metabolismo , Respuesta al Choque Térmico/efectos de los fármacos , Células 3T3 , Animales , Antibióticos Antineoplásicos/metabolismo , Benzoquinonas , Transformación Celular Viral , Proteínas de Unión al ADN/biosíntesis , Proteínas de Unión al ADN/genética , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Factores de Transcripción del Choque Térmico , Respuesta al Choque Térmico/fisiología , Humanos , Lactamas Macrocíclicas , Lactonas/metabolismo , Lactonas/farmacología , Macrólidos , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Ratones SCID , Papillomaviridae , Quinonas/metabolismo , Quinonas/farmacología , Rifabutina/análogos & derivados , Rifabutina/metabolismo , Rifabutina/farmacología , Factores de Transcripción , Activación Transcripcional/efectos de los fármacos , Ensayos Antitumor por Modelo de Xenoinjerto

RESUMEN

The benzoquinoid ansamycins geldanamycin (GA), herbimycin, and their derivatives are emerging as novel therapeutic agents that act by inhibiting the 90-kDa heat-shock protein hsp90. We report that GA inhibits the proliferation of mitogen-activated T cells. GA is actively toxic to both resting and activated T cells; activated T cells appear to be especially vulnerable. The mechanism by which GA acts is reflected by its effects on an essential hsp90-dependent protein, the T cell-specific nonreceptor tyrosine kinase lck. GA treatment depletes lck levels in cultured T cells by a kinetically slow dose-dependent process. Pulse-chase analyses indicate that GA induces the very rapid degradation of newly synthesized lck molecules. GA also induces a slower degradation of mature lck populations. These results correlate with global losses in protein tyrosine kinase activity and an inability to respond to TCR stimuli, but the activity of mature lck is not immediately compromised. Although the specific proteasome inhibitor lactacystin provides marginal protection against GA-induced lck depletion, proteasome inhibition also induces changes in lck detergent solubility independent of GA application. There is no other evidence for the involvement of the proteosome. Lysosome inhibition provides quantitatively superior protection against degradation. These results indicate that pharmacologic inhibition of hsp90 chaperone function may represent a novel immunosuppressant strategy, and elaborate on the appropriate context in which to interpret losses of lck as a reporter for the pharmacology of GA in whole organisms.

Asunto(s)

Inhibidores Enzimáticos/farmacología , Proteínas HSP90 de Choque Térmico/metabolismo , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Quinonas/farmacología , Linfocitos T/efectos de los fármacos , Linfocitos T/enzimología , Animales , Benzoquinonas , Células Cultivadas , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/farmacología , Inhibidores Enzimáticos/metabolismo , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Humanos , Inmunosupresores/farmacología , Células Jurkat , Lactamas Macrocíclicas , Activación de Linfocitos/efectos de los fármacos , Proteína Tirosina Quinasa p56(lck) Específica de Linfocito/antagonistas & inhibidores , Proteína Tirosina Quinasa p56(lck) Específica de Linfocito/biosíntesis , Masculino , Ratones , Ratones Endogámicos DBA , Mitógenos/inmunología , Complejos Multienzimáticos/metabolismo , Complejo de la Endopetidasa Proteasomal , Unión Proteica/efectos de los fármacos , Unión Proteica/inmunología , Proteínas Tirosina Quinasas/metabolismo , Quinonas/metabolismo , Bazo/citología , Bazo/inmunología , Linfocitos T/inmunología , Factores de Tiempo

RESUMEN

Although the use of tumor-derived heat shock/chaperone proteins (HSPs) as anticancer vaccines is gaining wider study and acceptance, there have thus far been no reports concerning chaperone antitumor activities against disseminated hematological malignancies. We have devised an efficient and effective method for purification of the chaperone proteins grp94/gp96, HSP90, HSP70, and calreticulin from harvested A20 murine leukemia/lymphoma tumor material. We have demonstrated that these purified proteins, when used as vaccines, can induce potent and specific immunity against a lethal tumor challenge. Individual chaperone proteins were differentially effective in their abilities to provide immune protection. The increase in survival generated by the most effective chaperone vaccine, HSP70, resulted from at least a 2-log reduction in tumor burden. Syngeneic granulocyte macrophage colony-stimulating factor producing fibroblasts were injected at the site of vaccination in an attempt to augment the immune response. Surprisingly, localized granulocyte macrophage colony-stimulating factor production inhibited the protective effects of chaperone vaccination. These studies provide evidence that chaperone proteins can be isolated from B-cell tumors and used effectively to immunize against disseminated lymphoid malignancies.

Asunto(s)

Leucemia de Células B/prevención & control , Linfoma de Células B/prevención & control , Chaperonas Moleculares/uso terapéutico , Células 3T3 , Animales , Proteínas de Unión al Calcio/aislamiento & purificación , Proteínas de Unión al Calcio/uso terapéutico , Calreticulina , Vacunas contra el Cáncer/aislamiento & purificación , Vacunas contra el Cáncer/uso terapéutico , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Factor Estimulante de Colonias de Granulocitos y Macrófagos/fisiología , Proteínas HSP70 de Choque Térmico/aislamiento & purificación , Proteínas HSP70 de Choque Térmico/uso terapéutico , Proteínas HSP90 de Choque Térmico/aislamiento & purificación , Proteínas HSP90 de Choque Térmico/uso terapéutico , Inmunidad , Inmunización , Leucemia de Células B/inmunología , Linfoma de Células B/inmunología , Proteínas de la Membrana/aislamiento & purificación , Proteínas de la Membrana/uso terapéutico , Ratones , Ratones Endogámicos BALB C , Chaperonas Moleculares/aislamiento & purificación , Ribonucleoproteínas/aislamiento & purificación , Ribonucleoproteínas/uso terapéutico , Análisis de Supervivencia , Resultado del Tratamiento , Células Tumorales Cultivadas

RESUMEN

Continuous venovenous hemofiltration/hemodiafiltration (CVVH/D) is commonly used to provide renal replacement therapy for critically ill patients who are hemodynamically unstable. Occasionally, the addition of plasmapheresis therapy is necessary for some conditions, including immune-mediated acute renal failure, sepsis, fulminant hepatic failure, and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Most tertiary care facilities provide centrifugation plasmapheresis instead of membrane plasmapheresis, because of the requirement for both therapeutic plasma exchange and pheresis of cellular blood products. We report a new technique where centrifugation plasmapheresis and CVVHD (P-CVVHD) are combined and used concurrently. Blood from the patient was concurrently filtered utilizing a Hospal BSM 22 machine with a Multiflow 60 hemofilter and a Cobe Spectra continuous cell separator in a parallel configuration. P-CVVHD is technically possible and can be used for long periods of time with limited risks. There may be advantages to P-CVVHD compared with discontinuous combined CVVH/D and plasmapheresis therapy.

Asunto(s)

Hemodiafiltración/métodos , Plasmaféresis/métodos , Adolescente , Ácido Cítrico/sangre , Femenino , Hemodiafiltración/instrumentación , Humanos , Pruebas de Función Renal , Leucemia Bifenotípica Aguda/complicaciones , Volumen Plasmático , Plasmaféresis/instrumentación , Desequilibrio Hidroelectrolítico/complicaciones , Desequilibrio Hidroelectrolítico/terapia

RESUMEN

Antisense RNA expression vectors have been developed relatively recently as a means to study the role of specific oncogenes in malignant transformation. In this paper, strategies for the construction of antisense plasmid vectors from commercially available reagents are described. Techniques for the introduction of these vectors into cell lines and tumors are also described and preferred methods for the evaluation of biological effects are presented. Lastly, using specific examples, the limitations and potential artifacts associated with antisense vector use in the study of tumorigenesis are discussed.

Asunto(s)

Regulación de la Expresión Génica/efectos de los fármacos , Oncogenes/genética , ARN sin Sentido/farmacología , Clonación Molecular , ADN Complementario/genética , Células Eucariotas , Citometría de Flujo , Marcación de Gen/métodos , Vectores Genéticos , ARN sin Sentido/biosíntesis , Transfección

RESUMEN

Members of the Hsp90 family of molecular chaperones play important roles in allowing some intracellular signaling molecules and transcription factors to reach and maintain functionally active conformations. In the present study, we have utilized the specific Hsp90-binding agent, geldanamycin, to examine the requirement for Hsp90 during zebrafish development. We show that geldanamycin interacts with both the alpha and the beta-isoforms of zebrafish Hsp90 and that geldanamycin-treated embryos consistently exhibit a number of defects in tissues which express either one of these genes. Within the somites, geldanamycin treatment results in the absence of eng-2-expressing muscle pioneer cells. However, early development of adaxial cells, which give rise to muscle pioneers and which strongly express the hsp90alpha gene shortly before muscle pioneer formation, appeared unaffected. Furthermore, development of the notochord, which provides many of the signals required for proper somite patterning and which does not express detectable levels of either hsp90alpha or hsp90beta mRNA, was similarly unaffected in geldanamycin-treated embryos. The data are consistent with there being a temporal and spatial requirement for Hsp90 function within somitic cells which is necessary for the formation of eng-2-expressing muscle pioneers and possibly other striated muscle fiber types.

Asunto(s)

Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Quinonas/farmacología , Somitos/efectos de los fármacos , Pez Cebra/embriología , Animales , Benzoquinonas , Western Blotting , Colforsina/farmacología , Embrión no Mamífero/efectos de los fármacos , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Proteínas de Homeodominio/genética , Lactamas Macrocíclicas , Músculos/efectos de los fármacos , Músculos/embriología , Proteínas del Tejido Nervioso/genética , Notocorda/embriología , Notocorda/metabolismo , Fenotipo , Proteínas de Pez Cebra

RESUMEN

To examine the biochemical mechanism by which hsp90 exerts its essential positive function on certain signal transduction proteins, we characterized the effects of molybdate and geldanamycin on hsp90 function and structure. Molybdate inhibited hsp90-mediated p56lck biogenesis and luciferase renaturation while enforcing salt-stable interactions with these substrates. Molybdate also reduced the amount of free hsp90 present in cell lysates, inhibited hsp90's ability to bind geldanamycin, and induced resistance to proteolysis at a specific region within the C-terminal domain of hsp90. In contrast, the hsp90 inhibitor geldanamycin prevented hsp90 from assuming natural or molybdate-induced conformations that allow salt-stable interactions with substrates. When these compounds were applied sequentially, the order of addition determined the effects observed, indicating that these agents had opposing effects on hsp90. We conclude that a specific region within the C-terminal domain of hsp90 (near residue 600) determines the mode by which hsp90 interacts with substrates and that the ability of hsp90 to cycle between alternative modes of interaction is obligatory for hsp90 function.

Asunto(s)

Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Molibdeno/farmacología , Secuencia de Aminoácidos , Animales , Benzoquinonas , Endopeptidasas/metabolismo , Inhibidores Enzimáticos/farmacología , Proteínas HSP90 de Choque Térmico/química , Proteínas HSP90 de Choque Térmico/inmunología , Proteínas HSP90 de Choque Térmico/metabolismo , Lactamas Macrocíclicas , Luciferasas/química , Datos de Secuencia Molecular , Fosfatos/farmacología , Conformación Proteica/efectos de los fármacos , Desnaturalización Proteica/efectos de los fármacos , Pliegue de Proteína , Quinonas/farmacología , Conejos , Reticulocitos/efectos de los fármacos , Reticulocitos/metabolismo , Especificidad por Sustrato

Asunto(s)

Chaperonas Moleculares/fisiología , Proteínas HSP70 de Choque Térmico , Humanos , Chaperonas Moleculares/química , Chaperonas Moleculares/inmunología , Pliegue de Proteína , Transducción de Señal

RESUMEN

Several lines of evidence now indicate that type 1 insulin-like growth factor receptor (IGF1R) function may be particularly important in the pathogenesis of the pediatric cancer neuroblastoma. Modulating the expression of specific genes involved in neuroblastoma tumorigenesis could provide a much needed alternative treatment strategy for poor prognosis disease. We now report construction of an antisense expression vector to the IGF1R that markedly reduces cellular IGF1R levels and inhibits the proliferation and clonogenicity of neuroblastoma cells in vitro but not that of IGF1R null cells. This antitumor activity is associated with the induction of apoptotic cell death in transfected cells, as measured by annexin V staining and flow cytometry. Direct injection of this vector into established tumors growing in syngeneic mice results in a marked inhibition of tumor growth with complete and durable tumor regression in one-half of the animals. This effect appears to be immunologically mediated in that vector injection of neuroblastoma tumors growing in severe combined immunodeficiency mice results in only modest delay of tumor growth. Our results suggest that inhibition of IGF1R expression by direct intratumoral delivery of an antisense construct could provide a novel therapeutic approach in the management of poor prognosis neuroblastoma.

Asunto(s)

Terapia Genética/métodos , Neuroblastoma/terapia , ARN sin Sentido/administración & dosificación , Receptor IGF Tipo 2/fisiología , Animales , Elementos sin Sentido (Genética) , Apoptosis/fisiología , División Celular/fisiología , ADN Complementario/genética , ADN Complementario/metabolismo , Modelos Animales de Enfermedad , Femenino , Vectores Genéticos , Inyecciones Intralesiones , Ratones , Ratones Endogámicos A , Ratones Endogámicos BALB C , Ratones SCID , Neuroblastoma/metabolismo , Neuroblastoma/patología , ARN sin Sentido/genética , ARN sin Sentido/metabolismo , Receptor IGF Tipo 2/antagonistas & inhibidores , Receptor IGF Tipo 2/biosíntesis , Transfección , Células Tumorales Cultivadas

RESUMEN

BACKGROUND: Smooth muscle cell (SMC) migration is a vital component in the response of the arterial wall to revascularization injury. Cell surface integrin-extracellular matrix interactions are essential for cell migration. SMCs express both beta1- and beta3-integrins. In this study, we examined the relative functional roles of beta1- and beta3-integrin-matrix interactions in postinjury SMC migration. METHODS AND RESULTS: Flow cytometry and fluorescence microscopy of migrating SMCs immunostained with anti-beta1 and anti-alpha(v)beta3/5 antibodies (Abs) revealed expression of both beta1- and beta3-integrins, with beta1 observed as linear streaks and beta3 found in focal contacts. In a scrape-wound migration assay, anti-beta1 Abs (92.0+/-10.7% of control, P=.1) and 0.5 mmol/L linear RGD (105+/-5% of control, P=.2) did not alter SMC migration at 48 hours after injury. Beta3-blockade, however, via Abs (anti-beta3/5 35.7+/-4.5% of control, anti-beta3 61+/-12% of control, both P<.001) and cyclic RGD (0.5 mmol/L) (12+/-10% of control, P<.001) decreased migration. Neither beta1- nor beta3-inhibition altered postinjury [3H]thymidine incorporation. In the rat carotid injury model, local adventitial polymer-based delivery of radiolabeled linear or cyclic RGD led to uptake and retention of label, for both peptides, over a 72-hour period after injury. Local arterial wall beta1-blockade via polymer-based delivery of linear RGD had no effect on SMC migration at 4.5 days (11.5+/-3.2 versus 12.8 SMCs per x600 field [control], P=.6) or on neointimal thickening at 14 days (I/M area ratio, 0.664+/-0.328 versus 1.179+/-0.324 [control], P=.6) after injury. In contrast, local beta3-blockade via cRGD limited migration (0.8+/-0.8 versus 12.8+/-4.4 SMCs per x600 field [control], P<.01) and thickening (I/M area ratio, 0.004+/-0.008 versus 1.179+/-0.324 [control], P<.01). CONCLUSIONS: In postinjury migrating SMCs, beta3- rather than beta1-integrin-matrix interactions are of greater functional significance in adhesive processes essential for SMC migration in vitro and in vivo. Blockade of dominant SMC integrin (beta3)-matrix interactions may be a valuable approach for limiting injury-induced SMC migration and late arterial renarrowing.

Asunto(s)

Antígenos CD/fisiología , Traumatismos de las Arterias Carótidas , Endotelio Vascular/lesiones , Matriz Extracelular/fisiología , Músculo Liso/fisiología , Glicoproteínas de Membrana Plaquetaria/fisiología , Animales , Arterias Carótidas/patología , Cateterismo/efectos adversos , Adhesión Celular , Movimiento Celular , Células Cultivadas , Endotelio Vascular/patología , Fibronectinas/farmacología , Citometría de Flujo , Integrina beta1/fisiología , Integrina beta3 , Microscopía Fluorescente , Músculo Liso/química , Oligopéptidos/farmacología , Oligopéptidos/fisiología , Ratas , Ratas Sprague-Dawley , Vitronectina/farmacología , Cicatrización de Heridas

RESUMEN

Wild-type p53 is a short-lived protein which turns over very rapidly via selective proteolysis in the ubiquitin-proteasome pathway. Most p53 mutations, however, encode for protein products which display markedly increased intracellular levels and are associated with positive tumor-promoting activity. The mechanism by which mutation leads to impairment of ubiquitination and proteasome-mediated degradation is unknown, but it has been noted that many transforming p53 mutants are found in stable physical association with molecular chaperones of the hsp70 class. To explore a possible role for aberrant chaperone interactions in mediating the altered function of mutant p53 and its intracellular accumulation, we examined the chaperone proteins which physically associate with a temperature-sensitive murine p53 mutant. In lysate prepared from A1-5 cells grown under mutant temperature conditions, hsp70 coprecipitated with p53Val135 as previously reported by others, but in addition, other well-recognized elements of the cellular chaperone machinery, including hsp90, cyclophilin 40, and p23, were detected. Under temperature conditions favoring wild-type p53 conformation, the coprecipitation of chaperone proteins with p53 was lost in conjunction with the restoration of its transcriptional activating activity. Chaperone interactions similar to those demonstrated in A1-5 cells under mutant conditions were also detected in human breast cancer cells expressing two different hot-spot mutations. To examine the effect of directly disrupting chaperone interactions with mutant p53, we made use of geldanamycin (GA), a selective hsp90-binding agent which has been shown to alter the chaperone associations regulating the function of unliganded steroid receptors. GA treatment of cells altered heteroprotein complex formation with several different mutant p53 species. It increased p53 turnover and resulted in nuclear translocation of the protein in A1-5 cells. GA did not, however, appear to restore wild-type transcriptional activating activity to mutant p53 proteins in either A1-5 cells or human breast cancer cell lines.

Asunto(s)

Proteínas Portadoras/metabolismo , Ciclofilinas , Inhibidores Enzimáticos/farmacología , Proteínas HSP70 de Choque Térmico/metabolismo , Proteínas HSP90 de Choque Térmico , Mutación , Isomerasa de Peptidilprolil/metabolismo , Fosfoproteínas/metabolismo , Quinonas/farmacología , Proteína p53 Supresora de Tumor/efectos de los fármacos , Animales , Benzoquinonas , Proteínas Portadoras/efectos de los fármacos , Línea Celular , Peptidil-Prolil Isomerasa F , Proteínas HSP70 de Choque Térmico/efectos de los fármacos , Humanos , Oxidorreductasas Intramoleculares , Lactamas Macrocíclicas , Ratones , Chaperonas Moleculares/metabolismo , Isomerasa de Peptidilprolil/efectos de los fármacos , Fosfoproteínas/efectos de los fármacos , Prostaglandina-E Sintasas , Ratas , Activación Transcripcional , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo

RESUMEN

Mutation of the tumor suppressor gene p53 is the most common genetic abnormality detected in human cancers. Wild type p53 is a short-lived protein with very low basal intracellular levels. Most mutated forms of the protein, however, display markedly increased intracellular levels as an essential feature of their positive transforming activity. In this report, we have used selective inhibitors of the 20S proteasome to demonstrate that processing of p53 by ubiquitination and proteasome-mediated degradation is impaired by commonly occuring mutations of the protein. We found that this impairment of p53 turnover can be reversed by treatment of tumor cells with the benzoquinone ansamycin, geldanamycin, leading to a marked reduction in intracellular p53 levels. Finally, using cells which over-express a mutant p53 protein, we were able to demonstrate that restoration of proteasome-mediated degradation by geldanamycin is accompanied by p53 polyubiquitination. Although much remains to be learned about the mechanisms involved, our data demonstrate that selective de-stabilization of mutant transforming proteins such as p53 can be achieved pharmacologically with agents such as geldanamycin which modify the function of molecular chaperone proteins within tumor cells.

Asunto(s)

Cisteína Endopeptidasas/metabolismo , Inhibidores Enzimáticos/farmacología , Complejos Multienzimáticos/metabolismo , Mutación , Quinonas/farmacología , Proteína p53 Supresora de Tumor/genética , Acetilcisteína/análogos & derivados , Acetilcisteína/metabolismo , Animales , Benzoquinonas , Cicloheximida/farmacología , Inhibidores de Cisteína Proteinasa/metabolismo , Detergentes/metabolismo , Semivida , Humanos , Lactamas Macrocíclicas , Leupeptinas/metabolismo , Ratones , Octoxinol , Polietilenglicoles/metabolismo , Complejo de la Endopetidasa Proteasomal , Inhibidores de la Síntesis de la Proteína/farmacología , Ratas , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/metabolismo , Ubiquitinas/metabolismo

RESUMEN

The purpose of the study was to assess myocardial glucose uptake in nondiabetic (n = 5) and streptozotocin-diabetic (n = 6) Yucatan miniature swine under matched hyperglycemic and hypoinsulinemic conditions. Fasting conscious diabetic swine had significantly higher plasma glucose levels (20.9 +/- 2.6 v 5.2 +/- 0.3 mmol/L) and lower insulin levels (6 +/- 1 v 14 +/- 4 microU/mL) than nondiabetic animals. Myocardial glucose uptake was measured in open-chest anesthetized animals under aerobic and ischemic conditions 12 weeks after streptozotocin treatment. Coronary blood flow was controlled by an extracorporeal perfusion circuit. Ischemia was induced by reducing left anterior descending (LAD) coronary artery blood flow by 60% for 40 minutes. Animals were treated with somatostatin to suppress insulin secretion, and nondiabetic swine received intravenous (IV) glucose to match the hyperglycemia in the diabetic animals. The rate of glucose uptake by the myocardium was not statistically different under aerobic conditions, but was significantly lower in diabetic swine during ischemia (0.20 +/- 0.08 v 0.63 +/- 0.14 micromol x g(-1) x min(-1), P < .01). Myocardial glucose transporter (GLUT4) protein concentration was decreased by 31% in diabetic swine. In conclusion, 12 weeks of streptozotocin diabetes in swine caused a significant decrease in myocardial GLUT4 protein and a decrease in myocardial glucose uptake during ischemia.

Asunto(s)

Diabetes Mellitus Experimental/metabolismo , Glucosa/metabolismo , Proteínas Musculares , Isquemia Miocárdica/metabolismo , Miocardio/metabolismo , Animales , Glucemia/análisis , Circulación Coronaria , Ayuno/metabolismo , Ácidos Grasos no Esterificados/sangre , Transportador de Glucosa de Tipo 4 , Insulina/análisis , Ácido Láctico/sangre , Masculino , Proteínas de Transporte de Monosacáridos/metabolismo , Porcinos , Porcinos Enanos , Función Ventricular/fisiología

RESUMEN

Arterial smooth muscle cell (SMC) proliferation is a significant component of post-angioplasty restenosis. We evaluated whether pre-conditioning of SMCs, via induction of the heat shock response prior to actual physical injury, would result in an alteration in cell proliferation following injury. Rat aortic SMCs were pretreated with either chemical or thermal heat shock inducers and then subjected to scrape-wound injury in vitro. Cell proliferation at 24 hrs was measured via 3H-thymidine (Tdr) incorporation and compared with scrape wounded unstressed controls. A significant decline in cell proliferation post scrape-wound injury was observed for both chemical and thermal heat shock pre-conditioned cultures, compared to untreated controls. Increased expression of heat shock protein 72 was confirmed serially throughout the 24 hr study period for both chemical and thermal inducers. Despite reduced proliferation heat shocked cells remained viable as evidenced by fluorescent cell viability assay and preserved migration. Pre-conditioning of SMCs through induction of the heat shock response prior to physical injury may be a useful approach to limit aggressive proliferation observed with mechanical revascularization injury.

Asunto(s)

División Celular/fisiología , Proteínas HSP90 de Choque Térmico/biosíntesis , Proteínas de Choque Térmico/biosíntesis , Músculo Liso Vascular/fisiopatología , Isquemia Miocárdica/patología , Animales , Aorta/citología , Aorta/metabolismo , Aorta/fisiopatología , Células Cultivadas , Fluoresceínas/metabolismo , Proteínas del Choque Térmico HSP72 , Proteínas HSP90 de Choque Térmico/metabolismo , Proteínas de Choque Térmico/metabolismo , Músculo Liso Vascular/citología , Músculo Liso Vascular/metabolismo , Isquemia Miocárdica/metabolismo , Ratas